Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, has been recently introduced for treatment of B cell malignancies, showing success in patients with CLL (Moreno et al., 2019). Here, BTK is linked to B-cell chronic lymphocytic leukemia.